Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $78 to $67.
Leerink Partners analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $78 to $67.